Introduction: This Italian multicenter retrospective study evaluated safety and efficacy of the anti-TNF drug, adalimumab, in a cohort of patients affected by tuberculosis (TB), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV). Psoriasis is an autoimmune disease affecting around 3% of the Italian population and associated with several comorbidities, including arthritis, cardio-metabolic diseases and depression. In its moderate-To-severe form, psoriasis profoundly impairs quality of life of patients. Aim: Therefore, these patients deserve systemic treatments including conventional DMARDS (disease modifying anti-rheumatic drugs) and biologics. Management of moderate and severe psoriasis patients affected ...
Background: Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disea...
Introduction: Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated diseases, and TNF-...
Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more sus...
Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setti...
BACKGROUND: Little data is available about the safety of TNF-\u3b1 inhibitors in patients with HCV a...
Adalimumab is a human, antitumour necrosis factor (TNF) monoclonal antibody with a high specificity...
There is much evidence to show the efficacy of adalimumab, a human monoclonal antibody targeting tum...
Background: Observational studies in daily practice are an essential complement to pivotal randomise...
Background: Observational studies in daily practice are an essential complement to pivotal randomise...
OBJECTIVE: The objective of this EBM review is to determine whether or not “Does adalimumab effectiv...
BACKGROUND: Observational studies in daily practice are an essential complement to pivotal randomis...
BACKGROUND: Observational studies in daily practice are an essential complement to pivotal randomis...
Background: Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disea...
Introduction: Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated diseases, and TNF-...
Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more sus...
Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setti...
BACKGROUND: Little data is available about the safety of TNF-\u3b1 inhibitors in patients with HCV a...
Adalimumab is a human, antitumour necrosis factor (TNF) monoclonal antibody with a high specificity...
There is much evidence to show the efficacy of adalimumab, a human monoclonal antibody targeting tum...
Background: Observational studies in daily practice are an essential complement to pivotal randomise...
Background: Observational studies in daily practice are an essential complement to pivotal randomise...
OBJECTIVE: The objective of this EBM review is to determine whether or not “Does adalimumab effectiv...
BACKGROUND: Observational studies in daily practice are an essential complement to pivotal randomis...
BACKGROUND: Observational studies in daily practice are an essential complement to pivotal randomis...
Background: Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disea...
Introduction: Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated diseases, and TNF-...
Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more sus...